论文部分内容阅读
ＯＸＩＧＥＮＥ公司正在对其抗癌新药ｃｏｍｂｒｅｔａｓ ｔａｔｉｎ进行三项Ⅰ /Ⅱ期临床研究 ,用于晚期实体瘤患者。这是唯一正在开发的作用为破坏肿瘤脉管系统的抗癌药。ｃｏｍｂｒｅｔａｓｔｅｔｉｎ的作用机制不同于血管生成抑制剂 ,如ＥｎｔｅｒＭｅｄ公司的ｅｎｄｏｓｔ
OXIGENE is conducting Phase I / II clinical studies of its anticancer drug combretas tatin for patients with advanced solid tumors. This is the only anti-cancer drug that is being developed to destroy the tumor vasculature. The mechanism of action of combretastetin is different from that of angiogenesis inhibitors, such as EnterMed’s endost